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Abstract 
Objectives: To systematically review all available evidence on efficacy and safety of 
cannabinoids for treating neurogenic lower urinary tract dysfunction (NLUTD) in 
patients with multiple sclerosis (MS). 
Patients and methods: The review was performed according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. 
Studies were identified by electronic search of Cochrane register, Embase, Medline, 
Scopus (last search on 11 November 2016). 
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Results: After screening 8469 articles, two randomized controlled trials and one 
open label study enrolling a total of 426 patients, were included. Cannabinoids 
relevantly decreased incontinence episodes in all three studies. Pooling data showed 
mean difference in incontinence episodes per 24 hours to be -0.35 (95% confidence 
interval -0.46 to -0.24). Mild adverse events were frequent (38-100%), but only two 
patients (0.7%) reported a serious adverse event. 
Conclusions: Preliminary data imply, that cannabinoids might be an effective and 
safe treatment option for NULTD in patients with MS. However, evidence base is 
poor and more high-quality, well-designed, adequately powered and sampled studies 
are urgently needed to reach definitive conclusions. 
 
1. Introduction 
Neurogenic lower urinary tract dysfunction (NLUTD) is highly prevalent in patients 
with multiple sclerosis (MS) and substantially impairs quality of life (1, 2). The 
prevalence of NLUTD appears to be related to the duration of MS and is reported by 
almost all patients suffering from MS for more than 10 years (1, 3). Treatment of 
NLUTD in the MS population is a significant challenge, especially since standard 
therapies often fail. Thus, therapeutic alternatives are urgently needed. 
Cannabinoids, a heterogenous group of endogenous molecules and others that are 
metabolites of phytocannabinoids (4), were reported to improve tremor and spasticity 
in animal models (5) and questionnaire-based reports suggested beneficial effects of 
recreational cannabis use in patients with MS suffering from NLUTD (6). 
Cannabinoids are presumed to reduce detrusor contractility via cannabinoid 
receptors (7, 8) expressed both in the detrusor and central nervous system (9). 
However, cannabinoid-mediated actions on lower urinary tract function are complex 
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and not yet fully understood. Considering the potential of cannabinoids for medical 
use (10), we performed a systematic review to assess and appraise the evidence on 
efficacy and safety of cannabinoids in the treatment of NLUTD in patients with MS. 
 
2.  Evidence acquisition 
 
2.1  Data sources and searches 
This systematic review was performed according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) Statement (11). A review 
protocol was elaborated, which is available on PROSPERO (CRD42014010142) 
(http://www.crd.york.ac.uk/PROSPERO). We systematically searched Cochrane 
Central Register of Controlled Trials, Embase, Medline, and Scopus from 1 January 
1946 to 11 November 2016. No language restriction was applied. We additionally 
searched the reference lists of all included studies and any relevant review articles. 
Moreover, we looked for (on 23 November 2016) unpublished (ongoing) research in 
ClinicalTrials.gov and the ISRCTN registry, but no additional studies have been 
identified. The search strategies are illustrated in Web supplement 1. 
 
2.2 Study selection 
We aimed to include all original studies that reported efficacy and/or safety data on 
cannabinoids for treating NLUTD in female and male patients with MS, including 
randomized controlled trials (RCTs), comparative non-RCTs, and single-arm cohort 
studies. Non-original articles, those including children only, and those not 
discriminating between patients with MS and other neurological/non-neurological 
disorders were excluded. All identified abstracts were imported into bibliography 
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management software (EndNote X7, Thomson Reuters, 1500 Spring Garden Street, 
Fourth Floor Philadelphia, PA 19130, USA) and filed according to inclusion and 
exclusion folders by drag and drop. Abstracts of all identified studies were 
independently reviewed by two authors (NAY, MPS and LM). Studies reporting on 
cannabinoids for treating NLUTD in patients with MS were reviewed in full text. 
 
2.3 Data extraction and risk of bias assessment 
The variables assessed included year of publication, type of study, type of 
cannabinoid, type of combination of cannabinoid, treatment duration, number of 
patients, gender and age, improvement of incontinence and nocturia episodes, 
number of daytime voids, adverse events and withdrawals. Data from eligible reports 
were extracted in duplicate (NAY and MPS) and discrepancies were resolved by a 
third reviewer (TMK). 
The Cochrane Risk of Bias Assessment tool was used for RCTs (12). This included 
the assessment of sequence generation, allocation concealment, blinding of 
participants, therapists, and outcome assessors, completeness of outcome data, and 
selective outcome reporting (Web supplement 2). The risk of bias in the comparative 
non-RCT was assessed using the Cochrane tool and an extra item to estimate the 
risk of findings being explained by confounding (Web supplement 2). This is a 
pragmatic approach recommended by methodological literature to assess risks of 
bias in non-randomized studies (13-15). A list of the 5 most important confounders 
for efficacy and safety outcomes was developed with clinical content experts 
(members of the International Continence Society Neuro-Urology Promotion 
Committee). The confounding factors are gender, age, urinary tract infections, 
degree of disability (Expanded Disability Status Scale (EDSS) / duration of 
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neurological disease) and other medications. In addition, external validity was taken 
into account by assessing whether study participants were selected consecutively 
and whether the specified confounding factors were comparable between the 
treatment groups. Attrition bias and selective outcome reporting were also assessed 
(Web supplement 2). This is also a pragmatic approach informed by the 
methodological literature (12). 
Finally, conflict of interest declaration, reporting of funding source and role of funding 
source was investigated. 
 
2.4 Data synthesis 
We constructed two-by-two tables for each of the included studies and calculated the 
effect size (ES) and corresponding 95% confidence intervals (CI). Since data were 
sparse, we performed only an exploratory analysis, ignoring differences in study 
design. The missing control group of the open label study was replaced by a norm-
control group, generated by the mean values of the two control groups from the 
RCTs. We pooled the effect size using a random effects model. Forest plots were 
generated in order to provide a visual representation of results and to illustrate the 
direction and magnitude of effects. Analyses were performed using the metan 
command of the Stata statistics software package (Stata 14.0 and 9.0 statistics 
software package; StataCorp 2009. Stata Statistical Software: Release 14. College 
Station, TX: StataCorp LP). 
Risk of bias summary and graph (Web supplement 2) was generated using 
Cochrane RevMan software (RevMan v 5.3; Informatics and Knowledge 
Management Department; Cochrane, St Albans House, 57-59 Haymarket, London, 
UK).  
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3. Evidence synthesis 
 
3.1 Search results 
The PRISMA flow diagram chart (Figure 1) illustrates the literature search and 
results. After screening of 8469 abstracts, 3 studies have been included in the 
qualitative and quantitative synthesis. 
 
3.2 Study and patient characteristics (Table 1) 
Two of the 3 included studies, were RCTs (16, 17) and one was an open label study 
(18). Overall, the 3 included studies enrolled a total of 426 patients: 289 women 
(68%), 122 men (29%), and 15 (3%) patients where the gender was not reported. 
The study by Brady et al. (18) was an open label study with a two phased follow up: 
initial combination therapy with 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) 
for eight weeks, followed by a single THC-only therapy for further eight weeks. 
 
3.3 Efficacy of cannabinoids 
Cannabinoids relevantly decreased incontinence episodes in all three studies (Table 
2). Pooling data showed mean difference in incontinence episodes per 24 hours to 
be -0.35 (95% confidence interval -0.46 to -0.24) (Figure 2). In addition, a significant 
decrease of nocturia episodes, number of daytime voids and number of voids per 24 
hours was found in one study (Table 2). 
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3.4 Safety of cannabinoids 
The most common adverse events are illustrated in Table 1. The general number of 
mild adverse events was high (38-100%), but only two patients (0.7%, 2/277 
patients) reported a serious adverse event (one haemorrhagic cystitis and one 
possible transient ischaemic attack, both with unclear causality). 
 
3.5 Risk of bias and confounding 
The risk of bias and confounding was high in the non-RCT (18) (Web supplement 2). 
 
3.6 Conflict of interest, funding source and role of founding source  
Conflict of interest was only disclosed by Kavia et al. (16). Non-company funding 
was reported by Brady et al. (18) and by Freeman et al. (17), whereas the study by 
Kavia et al. (16) was fully funded by the manufacturer company. None of the studies 
reported on the role of the founding source. 
 
4. Discussion 
 
4.1 Principal findings 
Improvements in incontinence rates, nocturia, daytime and 24-hour voids, as well as 
a limited number of severe adverse events suggest that cannabinoids may be 
effective and safe for treating NLUTD in patients with MS. Although our findings are 
promising, the evidence was confined to 3 studies with a very limited overall number 
of treated patients in this systematic review. 
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4.2 Findings in the context of existing evidence  
The endocannabinoid system is involved in regulation of LUT function, possibly at 
several levels of the micturition pathway (9). Studies in experimental animal models 
have demonstrated the role of the cannabinoid receptors in sensory signalling and 
afferent bladder functions, as well as a possible modulatory effect on cholinergic 
nerves (19). Fatty acid amide hydrolase (FAAH), which degrades endocannabinoids 
and fatty acid amides, is present both in the bladder mucosa and the central nervous 
system controlling lower urinary tract function. Inhibition of FAAH in rat models has 
been shown to be associated with a modulation of cannabinoid type 1 (CB1) and 
type 2 (CB2) receptors in the spinal cord. In addition, endogenous spinal 
cannabinoid receptor ligands seem to be involved in the regulation of normal 
micturition and detrusor overactivity (9, 20). 
Cannabis is one of the most popular recreational drugs worldwide and it is 
speculated that 178 million people in the age group 15 to 64 years have used it at 
least once in the year 2012 (10). There are approximately 60 pharmacologically 
active compounds extracted from the marijuana plant and the most popular is THC 
with psychoactive effects that are related to the concentration in the applied 
preparation (21). Because of the delay in onset of effect and narrow therapeutic 
window with resultant predilection for adverse effects, THC is administered in 
combination with another phytocannabinoid, such as CBD (22). Over the years, 
there has been a growing interest in the medical use of cannabis in treating disease 
and alleviating symptoms. Summarizing RCTs to assess the benefits and adverse 
events of cannabinoids, indicates that there is moderate-quality evidence supporting 
prescription cannabinoids as an effective and safe treatment of chronic neuropathic 
or cancer pain, sleep disorders and spasticity due to MS (10, 23). However, a 
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statistical significance was not reached in any of the clinical trials. Nevertheless, 
cannabinoids are particular interesting because of the favourable safety profile as 
severe side effects are very rare. 
 
4.3 Implications for research  
Prescription cannabinoids are becoming a well-established pharmacological 
treatment for pain and other diseases with a favourable safety profile (10). The 
preliminary data summarized in this systematic review suggests potential benefits of 
cannabinoids for treating NLUTD in both female and male patients with MS and 
therefore further clinical trials are warranted. Appropriately designed multicentric 
RCTs are necessary to assess validated disease- and condition-specific quality of 
life data, urodynamic findings, short-, medium- and long-term outcomes, safety, as 
well as cost-effectiveness issues. 
Despite many animal studies on cannabinoids and their function, the mechanism of 
action is not yet fully understood and in particular the effects of cannabinoids for 
treating NLUTD remain to be elucidated. Hence, further animal studies addressing 
the potential mechanism of action of cannabinoids for treating NLUTD are warranted. 
 
4.4 Implications for practice 
The progressive nature of the course of disease in MS influences NLUTD and 
thereby impacts the effect of therapy (1). Thus, cannabinoids might be successful at 
the beginning in a patient with MS but lose efficacy as the disease progresses. 
Nevertheless, cannabinoids open another therapeutic avenue for managing NLUTD 
in patients with MS. The safety profile is favourable and cannabinoids are devoid of 
the adverse effects associated with other more commonly used agents such as 
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blurred vision or constipation, which are particularly relevant in neurological patients. 
Moreover, this treatment is not associated with a risk for voiding dysfunction in 
contrast to most of the other therapeutic options and is particularly attractive to 
patients with MS where catheterisation and associated complications are a real 
concern. The general practitioner and/or neurologist may initiate the neuro-urological 
treatment considering that the risk of developing upper urinary tract damage and 
renal failure is much lower in patients with slowly progressive non-traumatic 
neurological disorders such as MS and Parkinson’s disease than in those with spinal 
cord injury or spina bifida (1). The treatment goals of cannabinoids vary between 
different neurological disorders. Thus, dose- and disease-specific studies are 
warranted and continuous versus on demand medication has to be further assessed. 
In addition, cannabinoids might be considered as a treatment improving different 
quality of life issues of the patient with MS including NLUTD. Taking into account the 
potential of cannabinoids in medical use (10), it seems worth to try it out before more 
invasive treatments are established. 
 
4.5 Limitations of this study 
Although this report represents, to the best of our knowledge, the first study that 
systematically reviewed and synthesized all available evidence of cannabinoids for 
treating NLUTD in patients with MS, there are limitations that should be addressed. 
The number of included articles, the number of investigated patients and the follow-
up was very limited. Moreover, the severity of MS and the NLUTD has not been 
reported. In addition, the missing control group of the open label study was replaced 
by a norm-control group generated by the mean values of the two control groups 
from the RCTs for statistical analysis. In the absence of robust evidence there is a 
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trade-off between the level of methodological rigor of an analysis and the efficiency. 
Using the base-rate of the two RCTs allowed us to incorporate the single-arm study. 
In view of the fact that any result derived from 2 or 3 studies will be exploratory, we 
decided to stick to this approach. Standard deviations for baseline and follow-up 
measurements were missing in most outcome measures and the between-study 
heterogeneity was substantial. More detailed methodological study limitations are 
described in Web supplement 3. 
 
5. Conclusions 
The currently available evidence implies that cannabinoids may be effective and safe 
for treating NLUTD in patients with MS. However, although we identified 2 RCTs, the 
reported outcomes, number of investigated patients and follow-up were very limited 
and the between-study heterogeneity was substantial. Thus, our systematic review, 
although suggesting that the treatment with cannabinoids seems to be a promising 
option for NLUTD in patients with MS, has shown the urgent need for well-designed, 
adequately sampled and powered RCTs to reach definitive conclusions. 
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Table 1. Characteristics of included studies 
 
 
Reference 
Year of 
publication 
Total 
number 
of 
patients 
(female/
male) 
Type of 
intervention 
Type of 
cannabinoid 
Dose/day 
in mg Application 
Treatment 
duration in 
weeks 
Mean 
age in 
years 
Mean MS 
duration 
in years 
Advers
e 
events: 
number 
of 
patient
s 
Most 
common 
type of 
adverse 
event, >5% 
of the 
patients 
(number of 
patients) 
Withdrawal: 
cause (number 
of patients) 
Outcome
s 
measured 
RCTs Freeman et al. [17] 2006 
81 
(52/29
) 
Control Placebo Max. 25 Capsule 13 50.2 NR 73 UTI NR IE24, PT 
   
86 
(62/24
) 
Experimental THC Max. 25 Capsule 13 49.9 NR 62 UTI NR IE24, PT 
   
88 
(60/28
) 
Experimental CBD Max. 25 Capsule 13 50.6 NR 64 UTI NR IE24, PT 
 Kavia et al. [16] 2010 
68 
(46/22
) 
Control Placebo 
Max. 
129/120 
Spray 8 47 NR 
18 
(2 SAE) 
Dizziness (4), 
UTI (4) 
Adverse event 
(3), Protocol 
deviation (1), 
Lost of follow 
up (1), Other 
(1) 
IE24, V24, 
NE, UED, 
DV 
   67 
(52/15
Experimental THC/CBD Max. Spray 8 48.6 NR 50 
Dizziness 
(12), 
Adverse event 
(7), withdrawal 
IE24, V24, 
NE, UED, 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
BEE = bladder emptying efficiency (=volume voided x 100/(volume voided + post void residual); CBD = cannabidiol; DV = daytime voids; IE24 = incontinence episodes per 24 hours; MCC = 
maximum cystometric capacity; MS = multiple sclerosis; NE = nocturia episodes (%); NR = not reported; PT = pad test; RCT = Randomized controlled trial; SAE = serious adverse event; 
THC = delta-9-tetrahydrocannabinol; UED = urgency episodes per day; UTI = urinary tract infection; V24 = voids per 24 hours 
  
) 129/120 (2 SAE) Headache 
(4), Vomiting 
(4) 
of consent (3), 
Other (1) 
DV 
Non-
RCT 
Brady et al. [18] 2004 21 (17/4) Experimental THC/CBD 
Max. 
120/120 
Spray 8 48 11 21 
Worsening of 
dry mouth 
MS relapse, 
reaction at 
dosing visit, 
UTIs, cardiac 
problems, 
failure to 
comply (5) 
IE24, DV, 
UED, NE, 
BEE, MCC 
   15 (NR) Experimental THC  Max. 120 Spray 8 48 NR 15 
Worsening of 
dry mouth 
Failure to 
comply (1) 
IE24, DV, 
UED, NE, 
BEE, MCC 
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Table 2. Treatment outcomes of included studies 
 
 
All reported values are means, except for * = median; ** = z value; † = percentage of patients reporting at least 1 urgency episode per day; BL = baseline; Con = control intervention; 
Exp = experimental intervention; NR = not reported; UT = under treatment; P-value = p-value of group comparison at same time point 
 
  
Incontinence episodes per 24 
hours Nocturia episodes Daytime voids Voids per 24 hours Urgency episodes per day 
Study 
Inter-
vention 
Number 
of 
patients BL UT Difference P-value BL UT Difference P-value BL UT Difference P-value BL UT Difference P-value BL UT Difference P-value 
 Con 81 1.4 0.568 (-18%) -2.76**   NR    NR    NR    NR  
Freeman et al. 
[17] Exp 86 2.5 1.864 (-33%) -5.63**   NR    NR    NR    NR  
 
Exp 
 
88 1.5 0.914 (-38%) -6.55**   NR    NR    NR    NR  
Kavia et al. [16] 
Con 64 2.1 1.12 -0.98 
0.569 
1.5 1.26 -0.24 
0.01 
NR NR -0.66 
0.044 
NR NR -0.9 
0.007 
NR NR -1.12 
0.07 
Exp  60 1.8 0.72 -1.08 1.6 1.08 -0.52 NR NR -1.23 NR NR -1.75 NR NR -1.88 
Brady et al. [18] 
Exp 13 2.14 0.9 -1.24* NR 1.79 0.8 -0.88 NR 10.2 7.38 -2.82 NR   NR  16† 6† -10† NR 
Exp 13 0.9 0.267 -0.63* NR 0.9 0.9 0 NR 7.38 6.43 -0.95 NR   NR  6† 4† -2† NR 
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